Jose Lutzky

12PUBLICATIONS
72CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 10, 2024
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.

Rino S Seedor, Andrew E Aplin, Corine Bertolotto

|Apr 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

James Larkin, Michele Del Vecchio, Mario Mandalá

|Jan 18, 2023
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.

Jose Lutzky, Ryan J Sullivan, Justine V Cohen

|Aug 08, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.

Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan

|May 11, 2022
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

Gino Kim In, Aparna Nallagangula, Jacob Seung Choi

|Oct 02, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.

Craig L Slingluff, Karl D Lewis, Robert Andtbacka

Pageof 2

Frequent Collaborators

4 joint publications

Paolo Antonio Ascierto

3 joint publications

Marcus O Butler

3 joint publications

Jeffrey Weber

3 joint publications

Nikhil I Khushalani